Liquidia Corporation
LQDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The $6.15B market capitalization puts LQDA squarely in mid-cap range for its industry. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Market Cap
$6.15B
Beta
0.54
P/E (TTM)
49.04
P/E (Fwd)
12.15
EPS (TTM)
$1.40
EPS (Fwd)
$5.65
ROE
131.8%
ROA
27.0%
Cash
$284.2M
Total Debt
$182.9M
Free CF
$74.3M
52W Change
147.0%
Annual Financials
Cash vs Debt
Where LQDA stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, LQDA finished 21.49% above its 150-day moving average ($56.11) and 34.88% above its 200-day moving average ($50.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LQDA overbought or oversold?
At the September 1, 2026 close, LQDA's RSI(14) was 24.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Liquidia Corporation holds $284.2M in cash against $182.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $74.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 131.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 27.0% further supports the picture of efficient asset utilization. Revenue has grown from $15.9M (2022) to $158.3M (2025), reflecting a 894% increase over the period.
LQDA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Liquidia Corporation's trajectory.